Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track OSTX with free AI briefings, catalyst countdowns, and dilution alerts.

OSTX · OS Therapies Incorporated

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$431,816 Cash on Hand
0.3mo Cash Runway
6.3% Short Interest
$8.25 Analyst Target (4)
Follow OSTX by email Get an email when OSTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about OSTX, unsubscribe in one click. Privacy

📣 What OSTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
LmddA-LLO-chHER2 Fusion Protein-secreting… Bone Cancer Phase 2 · NCT04974008 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

OSTX holds $431,816 in cash and short-term investments (as of Sep 30, 2026) and burns about $5.1M/quarter from operations, an estimated runway of 0.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 84 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OSTX files for a raise →

👥 Who Owns OSTX

Insiders 12.7% Other 5%+ holders 10.4% Institutions (32 holders) 5.6% Public and other holders 71.3%
HolderTypeShares% of sharesAs of
Thomas A. Satterfield, Jr. 5%+ holder (13G) 5,434,150 10.39% 2026-09-30
Shalom Auerbach
Former 10% Owner
Insider 2,677,570 5.12% 2025-07-29
Paul A. Romness
President and CEO, Director · +3.40M options
Insider 2,473,000 4.73% 2026-10-22
Vanguard Capital Management LLC Institution (13F) 777,651 1.49% 2026-09-30
John Ciccio
Director · +530,000 options
Insider 455,835 0.87% 2026-10-22
Theodore F. Search
Director · +530,000 options
Includes shares also reported by John Ciccio, counted once
Insider 455,835 0.87% 2026-10-22
Geode Capital Management, LLC Institution (13F) 370,948 0.71% 2026-09-30
Knuettel II Francis
Chief Financial Officer · +1.05M options
Insider 270,000 0.52% 2026-11-10
Howard Financial Services, Ltd. Institution (13F) 248,001 0.47% 2026-09-30
Citadel Advisors Llc Institution (13F) 245,856 0.47% 2026-09-30
Blackrock Inc. Institution (13F) 245,147 0.47% 2026-09-30
Colin Goddard
Director · +400,000 options
Insider 225,179 0.43% 2024-12-31

Share count 52,300,709 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-10
filed 2026-11-12
Francis Knuettel II
Award (A) 250,000 – 250,000
2026-11-10
filed 2026-11-12
Francis Knuettel II
Option award (A) 750,000 – –
2026-11-10
filed 2026-11-12
Clem Kerry M
Award (A) 200,000 – 225,000
2026-11-10
filed 2026-11-12
Clem Kerry M
Option award (A) 700,000 – –
2026-10-22
filed 2026-10-30
Francis Knuettel II
Option award (A) 300,000 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full OSTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OSTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.